Jaguar Health Reports Third-Quarter Revenue Decline
Quarterly revenue fell to $2.343 million as the company warned its cash cannot fund operations for one year.
Updated on Nov. 16, 2026 in Corporate Finance

Jaguar Health reported $2.343 million in third-quarter revenue for the quarter ended Sept. 30, 2026, down from $3.083 million a year earlier. The company also warned that its $5.528 million in cash cannot fund its operating plan for one year, raising substantial doubt about its ability to continue operating.
Why it matters
Revenue was concentrated heavily in a single partner, with Woodward accounting for about 98% of quarterly revenue, leaving the company exposed to that relationship. The going-concern warning signals that Jaguar Health will need additional financing or other changes to sustain operations beyond the coming year.
Product revenue fell from $3.041 million to $551,000, while license revenue rose from $42,000 to $1.792 million after a $1.8 million Woodward holdback was recognized. Basic and diluted net loss per share was $9.23 on a weighted average of 684,374 common shares.
The players
Jaguar Health, Inc.
Jaguar Health is a publicly traded pharmaceutical company that markets gastrointestinal and related therapies, with its products commercialized in the U.S. through partner Woodward.
The details
Revenue growth from licensing was driven by conditions on a Woodward holdback being met during the quarter, which allowed Jaguar Health to recognize the license revenue. Woodward holds exclusive U.S. commercialization rights for Mytesi and Canalevia-CA1 under the company's agreements, and share and per-share figures were retroactively adjusted for reverse stock splits.
Timeline
Sept. 30, 2026: Quarter end for the reported third-quarter results and cash balance.
Nov. 14, 2026: TokenPost included JAGX in its premarket earnings schedule.
Nov. 17, 2026, 8:30 a.m. ET: Scheduled investor webcast to review third-quarter results.
Corporate Finance Context
The going-concern warning places Jaguar Health among small pharmaceutical filers whose reported licensing gains can mask weak product sales and thin cash reserves. Its dependence on a single partner for nearly all revenue mirrors a recurring pattern in microcap biotech financing.
Shareholders face the prospect of dilution or restructuring if the company must raise new capital to meet its operating plan. Anyone holding the stock should weigh the going-concern warning against the company's limited cash reserves and heavy reliance on a single partner.
The takeaway
A single quarter of licensing revenue can lift reported results without solving a cash shortfall, so investors should read going-concern language alongside the balance sheet. Watch for management's funding plan, which the company has not yet detailed.
What happens next
Jaguar Health's investor webcast is scheduled for Nov. 17, 2026, at 8:30 a.m. ET, where management will review third-quarter results and provide corporate updates.
Further reading
For more on how companies report funding risk to investors, explore Corporate Finance coverage.






